Calcium channel agonists and dystonia in the mouse

Movement Disorders

Volumn 15, Issue 3, 2000, Pages 542-551

  Jinnah, H A ^a   Sepkuty, Jehuda P ^a   Ho, Tony ^a   Yitta, Silaja ^a   Drew, Touby ^a   Rothstein, Jeffrey D ^a   Hess, E J ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Animal model; EEG; EMG; Epilepsy; Seizure

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 4 (2 BENZYLBENZOYL) 2,5 DIMETHYL 1H PYRROLE 3 CARBOXYLIC ACID METHYL ESTER; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL STIMULATING AGENT; DIHYDROPYRIDINE; DILTIAZEM; FLUNARIZINE; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DYSTONIA; ELECTROENCEPHALOGRAM; ELECTROMYOGRAM; LOCOMOTION; MOTOR DYSFUNCTION; MOTOR UNIT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

3-PYRIDINECARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-5-NITRO-4-(2-(TRIFLUOROMETHYL)PHENYL)-, METHYL ESTER; ANIMALS; BRAIN MAPPING; CALCIUM CHANNEL AGONISTS; CALCIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIA; ELECTROENCEPHALOGRAPHY; ELECTROMYOGRAPHY; LOCOMOTION; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEUROLOGIC EXAMINATION; PYRROLES;

EID: 0034034781     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200005)15:3<542::AID-MDS1019>3.0.CO;2-2     Document Type: Article

References (47)

1. Fahn S. Concept and classification of dystonia. Adv Neurol 1988; 50:1-8.
2. Jankovic J, Fahn S. Dystonic disorders. In: Jankovic J, Tolosa E, eds. Parkinson's Disease and Movement Disorders. Baltimore, MD: Williams & Wilkins, 1998:513-551.
3. Marsden CD, Obeso JA, Zarranz JJ. The anatomical basis of symptomatic dystonia. Brain 1985;108:463-483.
4. McGeer EG, McGeer PL. The dystonias. Can J Neurol Sci 1988; 15:447-483.
5. Berardelli A, Rothwell JC, Hallett M, Thompson PD, Manfredi M, Marsden CD. The pathophysiology of primary dystonia. Brain 1998;121:1195-1212.
6. Spinella GM, Sheridan PH. Research opportunities in dystonia. Neurology 1994;44:1177-1179.
7. Duchen LW, Strich ST, Falconer DS. Clinical and pathological studies of an hereditary neuropathy in mice, dystonia musculorum. Brain 1964;87:367-378.
8. Richter A, Loscher W. Pathology of idiopathic dystonia: findings from genetic animal models. Prog Neurobiol 1998;54:633-677.
9. Brown A, Bernier G, Mathieu M, Rossant J, Kothary R. The mouse dystonia gene is a neural isoform of bullous pemphigoid antigen 1. Nat Genet 1995;10:301-306.
10. Lorden JF, McKeon TW, Baker HJ, Cox N, Walkley SU. Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans. J Neurosci 1984;4:1925-1932.
11. Lorden JF. Animal models of dystonia. In: Tsui JKC, Calne DB, eds. Handbook of Dystonia. New York, NY: Marcel Dekker, 1995: 5-42.
12. Loscher W, Fisher JE, Schmidt D, Fredow G, Honack D, Iturrian WB. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Mov Disord 1989;4:219-232.
13. Sprunger LK, Escayg A, Tallaksen-Greene S. Albin RL, Meisler MH. Dystonia associated with mutation of the neuronal sodium channel Scn8a and identification of the modifier locus Scnml on mouse chromosome 3. Hum Mol Genet 1999;8:471-479.
14. Campbell DB, Hess EJ. L-type calcium channels contribute to the tottering mouse dystonic episodes. Mol Pharmacol 1999;55:23-31.
15. Rampe D, Lacerda AE. A new site for the activation of cardiac calcium channels defined by the nondihydropyridine FPL 64176. J Pharmacol Exp Ther 1991;259:982-987.
16. 2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol 1991;40:734-741.
17. Triggle DJ, Janis RA. Calcium channel ligands. Annu Rev Pharmacol Toxicol 1987;27:347-369.
18. De Sarro G, Ascioti C, Di Paola ED, Vidal MJ, De Sarro A. Effects of antiepileptic drugs, calcium channel blockers, and other compounds on seizures induced by activation of voltage-dependent L calcium channel in DBA/2 mice. Gen Pharmacol 1992;23:1205-1216.
19. Bolger GT, Weissman BA, Skolnick P. The behavioral effects of the calcium agonist Bay K 8644 in the mouse: antagonism by the calcium antagonist nifedipine. Naunyn-Schmiedeberg's Arch Pharmacol 1985;328:373-377.
20. Peterson RN. Bay K 8644 induces a reversible spasticity-like syndrome in rats. Eur J Pharmacol 1986;130:323-326.
21. O'Neill SK, Bolger GT. Enantiomer selectivity and the development of tolerance to the behavioral effects of the calcium channel activator Bay K 8644. Brain Res Bull 1988;21:865-872.
22. Shelton RC, Grebb JA, Freed WJ. Induction of seizures in mice by intracerebroventricular administration of the calcium channel agonist Bay K 8644. Brain Res 1987;402:399-402.
23. Bourson A, Moser PC, Gower AJ, Mir AK. Central and peripheral effects of the dihydropyridine calcium channel activator Bay K 8644 in the rat. Eur J Pharmacol 1989;160:339-347.
24. Bianchi M, Rovati LC, Sacerdote P, Mantegassa P, Panerai AE. Effect of drugs belonging to different classes of calcium channel blockers on experimental seizures induced by the calcium channel agonist Bay K 8644. Neurosci Res 1990;6:157-162.
25. Palmer GC, Stagnitto ML, Ray RK, Knowles MA, Harvey R, Garske GE. Anticonvulsant properties of calcium channel blockers in mice: N-methyl-D,L-aspartate-and Bay K 8644-induced convulsions are potently blocked by the dihydropyridines. Epilepsia 1993;34:372-380.
26. ++ channel activators. Bay K 8644 and FPL 64176. J Pharmacol Exp Ther 1993;265:1125-1130.
27. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. New York, NY: Academic Press, 1997.
28. Fray PJ, Sahakian BJ, Robbins TW, Koob GF, Iversen SD. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology 1980;69:253-259.
29. Jinnah HA, Yitta S, Drew T, Kim BS, Visser JE, Rothstein JD. Calcium channel activation and self-biting in mice. Proc Natl Acad Sci USA 1999;96:15228-15232.
30. O'Neill SK, McKay DW, Campbell N, Triggle CR. Crowley M, Bolger GT. Comparative behavioral, neurochemical, and pharmacological activities of dihydropyridine calcium channel activating drugs. J Pharmacol Exp Ther 1990;253:905-910.
31. Rothwell J, Obeso JA. The anatomical and physiological basis of torsion dystonia. In: Marsden CD, Fahn S. eds. Movement Disorders 2. New York, NY: Butterworths, 1987:313-331.
32. De Sarro GB, Meldrum BS, Nistico G. Anticonvulsant effects of some calcium entry blockers in DBA/2 mice. Br J Pharmacol 1988;93:247-256.
33. Greenberg DA. Calcium channels in neurological disease. Ann Neurol 1997;42:275-282.
34. Barchi RL. Ion channel mutations affecting muscle and brain. Curr Opin Neurol 1998;11:461-468.
35. Catterall WA. Structure and function of voltage-gated ion channels. Anna Rev Biochem 1995;64:493-531.
36. McGeer EG, McGeer PL. Pathology of dystonias. In: Tsui JKC, Calne DB, eds. Handbook of Dystonia. New York, NY: Marcel Dekker, 1995:77-102.
37. 2+ channel antagonists in a hamster model of idiopathic dystonia. Eur J Pharmacol 1996;300:197-202.
38. Abad V, Ovsiew F. Treatment of persistent myoclonic tardive dystonia with verapamil. Br J Psychiatry 1993;162:554-556.
39. Cates M, Lusk K, Wells BG. Are calcium-channel blockers effective in the treatment of tardive dyskinesia? Ann Pharmacother 1993;27:191-196.
40. Marti-Masso JF, Poza JJ. Cinnarizine-induced parkinsonism: ten years later. Mov Disord 1998;13:453-456.
41. Dick RS, Barold SS. Diltiazem-induced parkinsonism. Am J Med 1989;87:95-96.
42. Garcia-Albia E, Jimenez-Jimenez FJ, Ayuso-Peralta L. Parkinsonism unmasked by verapamil. Clin Neuropharmacol 1993;16:263-265.
43. Sempere AP, Duarte J, Cabezas C. Parkinsonism induced by amlodipine. Mov Disord 1995;10:115-116.
44. Nakamishi K, Shimoda M, Kuno N. Takahashi K. Temporary symptom worsening caused by manidipine hydrochloride in two patients with Parkinson's disease. Mov Disord 1994;9:106-118.
45. Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine-and flunarizine-induced parkinsonism. Mov Disord 1997;12:107-112.
46. Micheli EF, Fernandez PM, Giannaula R. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 1989; 4:136-139.
47. Garcia-Ruiz P, Garci de Yebenes J, Jimenez-Jimenez FJ. Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 1992;15:19-26.